Role of Basic Fibroblast Growth Factor in Cancer: Biological Activity, Targeted Therapies, and Prognostic Value

Ardizzone, Alessio; Bova, Valentina; Casili, Giovanna; Repici, Alberto; Lanza, Marika; Giuffrida, Raffaella; Colarossi, Cristina; Mare, Marzia; Cuzzocrea, Salvatore; Esposito, Emanuela; Paterniti, Irene

doi:10.3390/cells12071002

Cited by 20 publications

(10 citation statements)

References 214 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, FGF2 plays a crucial role in the development and function of multiple organ systems. Preclinical studies have shown that FGF2 improves myocardial perfusion, provides cardioprotection during ischemia‐reperfusion injury, and exhibits anti‐cardiac hypertrophy effects 13 . According to colocalisation‐IF, FGF2 might be an interactive factor of Thbs1 (Figure 4F).…”

Section: Resultsmentioning

confidence: 96%

“…Preclinical studies have shown that FGF2 improves myocardial perfusion, provides cardioprotection during ischemia-reperfusion injury, and exhibits anti-cardiac hypertrophy effects. 13 According to colocalisation-IF, FGF2 might be an interactive factor of Thbs1 (Figure 4F). These findings demonstrate that…”

Section: Thbs1 Mediated Ecm-related Cytokines Via the Fgfr3/p-fgfr3 S...mentioning

confidence: 96%

See 1 more Smart Citation

Targeting Thbs1 reduces bladder remodeling caused by partial bladder outlet obstruction via the FGFR3/p‐FGFR3 pathway

Long,

Yang,

Yang

et al. 2023

Neurourology and Urodynamics

View full text Add to dashboard Cite

BackgroundPartial bladder outlet obstruction (pBOO) may lead to bladder remodeling, including fibrosis and extracellular matrix (ECM) deposition. Despite the extensive research on the mechanisms underlying pBOO, potential therapeutic targets for the treatment of pBOO require further research. Dysregulated expression of thrombospondin‐1 (Thbs1) has been reported in various human fibrotic diseases; however, its relationship with pBOO remains unclear.AimsInvestigate the effects of Thbs1 on bladder remodeling caused by pBOO.MethodsWe established a pBOO model in Sprague–Dawley rats and performed urodynamic analyses to estimate functional changes in the bladder, validated the histopathological changes in the bladder by using haematoxylin–eosin and Masson's trichrome staining, identified key target genes by integrating RNA sequencing (RNA‐seq) and bioinformatics analyses, validated the expression of related factors using Western blot analysis and RT‐qPCR, and used immunofluorescence staining to probe the potential interaction factors of Thbs1.ResultsUrodynamic results showed that pressure‐related parameters were significantly increased in rats with pBOO. Compared with the sham group, the pBOO group demonstrated significant increases in bladder morphology, bladder weight, and collagen deposition. Thbs1 was significantly upregulated in the bladder tissues of rats with pBOO, consistent with the RNA‐seq data. Thbs1 upregulation led to increased expression of matrix metalloproteinase (MMP) 2, MMP9, and fibronectin (Fn) in normal human urinary tract epithelial cells (SV‐HUC‐1), whereas anti‐Thbs1 treatment inhibited the production of these cytokines in TGF‐β1‐treated SV‐HUC‐1. Further experiments indicated that Thbs1 affected bladder remodeling in pBOO via the fibroblast growth factor receptor 3 (FGFR3) pathway.ConclusionsThbs1 plays a crucial role in bladder remodeling caused by pBOO. Targeting Thbs1 might alleviate ECM damage. Mechanistically, Thbs1 may function via the FGFR signaling pathway by regulating the FGFR3 receptor, identified as the most relevant disease target of pBOO, and FGF2 may be a mediator. These findings suggest that Thbs1 plays a role in BOO development and is a therapeutic target for this condition.

show abstract

Section: Resultsmentioning

confidence: 96%

Section: Thbs1 Mediated Ecm-related Cytokines Via the Fgfr3/p-fgfr3 S...mentioning

confidence: 96%

Targeting Thbs1 reduces bladder remodeling caused by partial bladder outlet obstruction via the FGFR3/p‐FGFR3 pathway

Long,

Yang,

Yang

et al. 2023

Neurourology and Urodynamics

View full text Add to dashboard Cite

show abstract

“…Basic fibroblast growth factor (bFGF) can be involved in many biological processes such as angiogenesis, wound healing, neurogenesis, cellular differentiation and migration, and it can bind to all receptors ( 165 ). It has been found that the prepared bFGF-gel dressing effectively promotes wound healing in rats.…”

Section: Classification and Active Ingredients Of Dressingsmentioning

confidence: 99%

Current status and progress in research on dressing management for diabetic foot ulcer

Jiang,

Li,

Luo

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

Diabetic foot ulcer (DFU) is a major complication of diabetes and is associated with a high risk of lower limb amputation and mortality. During their lifetime, 19%–34% of patients with diabetes can develop DFU. It is estimated that 61% of DFU become infected and 15% of those with DFU require amputation. Furthermore, developing a DFU increases the risk of mortality by 50%–68% at 5 years, higher than some cancers. Current standard management of DFU includes surgical debridement, the use of topical dressings and wound decompression, vascular assessment, and glycemic control. Among these methods, local treatment with dressings builds a protective physical barrier, maintains a moist environment, and drains the exudate from DFU wounds. This review summarizes the development, pathophysiology, and healing mechanisms of DFU. The latest research progress and the main application of dressings in laboratory and clinical stage are also summarized. The dressings discussed in this review include traditional dressings (gauze, oil yarn, traditional Chinese medicine, and others), basic dressings (hydrogel, hydrocolloid, sponge, foam, film agents, and others), bacteriostatic dressings, composite dressings (collagen, nanomaterials, chitosan dressings, and others), bioactive dressings (scaffold dressings with stem cells, decellularized wound matrix, autologous platelet enrichment plasma, and others), and dressings that use modern technology (3D bioprinting, photothermal effects, bioelectric dressings, microneedle dressings, smart bandages, orthopedic prosthetics and regenerative medicine). The dressing management challenges and limitations are also summarized. The purpose of this review is to help readers understand the pathogenesis and healing mechanism of DFU, help physicians select dressings correctly, provide an updated overview of the potential of biomaterials and devices and their application in DFU management, and provide ideas for further exploration and development of dressings. Proper use of dressings can promote DFU healing, reduce the cost of treating DFU, and reduce patient pain.

show abstract

“…Furthermore, stimulation of EGFR can activate downstream transcription factors, such as hypoxia-induced factor 1 (HIF-1), which will stimulate the production of VEGF genes, genes that will trigger the synthesis of pro-angiogenic VEGF molecules via the translation process. Pro-angiogenic molecules, such as VEGF, bFGF, and HIF-1, are thus boosted through these several processes, promoting the proliferation, migration, and formation of new blood vessels [ 25 , 42 , 43 , 44 , 45 ]. Figure 1 depicts the several pathways that will be activated upon receptor stimulation that ultimately contribute to the process of angiogenesis.…”

Section: The Epidermal Growth Factor (Egf) Family Their Receptors And...mentioning

confidence: 99%

Angiogenesis in Lung Cancer: Understanding the Roles of Growth Factors

Ngaha,

Zhilenkova,

Essogmo

et al. 2023

Cancers

View full text Add to dashboard Cite

Research has shown the role of growth factors in lung cancer angiogenesis. Angiogenesis promotes lung cancer progression by stimulating tumor growth, enhancing tumor invasion, contributing to metastasis, and modifying immune system responses within the tumor microenvironment. As a result, new treatment techniques based on the anti-angiogenic characteristics of compounds have been developed. These compounds selectively block the growth factors themselves, their receptors, or the downstream signaling pathways activated by these growth factors. The EGF and VEGF families are the primary targets in this approach, and several studies are being conducted to propose anti-angiogenic drugs that are increasingly suitable for the treatment of lung cancer, either as monotherapy or as combined therapy. The efficacy of the results are encouraging, but caution must be placed on the higher risk of toxicity, outlining the importance of personalized follow-up in the management of these patients.

show abstract

Role of Basic Fibroblast Growth Factor in Cancer: Biological Activity, Targeted Therapies, and Prognostic Value

Cited by 20 publications

References 214 publications

Targeting Thbs1 reduces bladder remodeling caused by partial bladder outlet obstruction via the FGFR3/p‐FGFR3 pathway

Targeting Thbs1 reduces bladder remodeling caused by partial bladder outlet obstruction via the FGFR3/p‐FGFR3 pathway

Current status and progress in research on dressing management for diabetic foot ulcer

Angiogenesis in Lung Cancer: Understanding the Roles of Growth Factors

Contact Info

Product

Resources

About